Cargando…

Drug-related problems in patients with rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) patients are at risk of acquiring drug-related problems (DRPs). However, there has been a lack of studies on DRPs in patients with RA up to now. METHOD: This retrospective study was conducted in a tertiary hospital in Malaysia from January 2012 to December 2017...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shu Ning, Zaman Huri, Hasniza, Yahya, Fariz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432894/
https://www.ncbi.nlm.nih.gov/pubmed/30962689
http://dx.doi.org/10.2147/TCRM.S194921
_version_ 1783406219302535168
author Ma, Shu Ning
Zaman Huri, Hasniza
Yahya, Fariz
author_facet Ma, Shu Ning
Zaman Huri, Hasniza
Yahya, Fariz
author_sort Ma, Shu Ning
collection PubMed
description BACKGROUND: Rheumatoid arthritis (RA) patients are at risk of acquiring drug-related problems (DRPs). However, there has been a lack of studies on DRPs in patients with RA up to now. METHOD: This retrospective study was conducted in a tertiary hospital in Malaysia from January 2012 to December 2017 with the purpose of assessing DRPs in RA patients and factors associated with its occurrence. A total of 200 patients who had received pharmacological treatment for RA were enrolled in this study. Assessment of DRPs was based on the Pharmaceutical Network Care Europe tool version 5.01. RESULTS: A total of 289 DRPs with an average of 1.5±1.0 problems per patient were identified, in which 78.5% of the population had at least one DRP. The most common DRPs encountered were adverse reactions (38.8%), drug interactions (33.6%), and drug-choice problems (14.5%). Factors that had significant association with the occurrence of DRPs were polypharmacy (P=0.003), multiple comorbidities (P=0.001), hyperlipidemia (P=0.009), osteo (P=0.040), and renal impairment (P=0.044). These data indicated that the prevalence of DRPs was high among RA patients. CONCLUSION: Early identification of types of DRPs and associated factors may enhance the prevention and management of RA.
format Online
Article
Text
id pubmed-6432894
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64328942019-04-08 Drug-related problems in patients with rheumatoid arthritis Ma, Shu Ning Zaman Huri, Hasniza Yahya, Fariz Ther Clin Risk Manag Original Research BACKGROUND: Rheumatoid arthritis (RA) patients are at risk of acquiring drug-related problems (DRPs). However, there has been a lack of studies on DRPs in patients with RA up to now. METHOD: This retrospective study was conducted in a tertiary hospital in Malaysia from January 2012 to December 2017 with the purpose of assessing DRPs in RA patients and factors associated with its occurrence. A total of 200 patients who had received pharmacological treatment for RA were enrolled in this study. Assessment of DRPs was based on the Pharmaceutical Network Care Europe tool version 5.01. RESULTS: A total of 289 DRPs with an average of 1.5±1.0 problems per patient were identified, in which 78.5% of the population had at least one DRP. The most common DRPs encountered were adverse reactions (38.8%), drug interactions (33.6%), and drug-choice problems (14.5%). Factors that had significant association with the occurrence of DRPs were polypharmacy (P=0.003), multiple comorbidities (P=0.001), hyperlipidemia (P=0.009), osteo (P=0.040), and renal impairment (P=0.044). These data indicated that the prevalence of DRPs was high among RA patients. CONCLUSION: Early identification of types of DRPs and associated factors may enhance the prevention and management of RA. Dove Medical Press 2019-03-21 /pmc/articles/PMC6432894/ /pubmed/30962689 http://dx.doi.org/10.2147/TCRM.S194921 Text en © 2019 Ma et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Ma, Shu Ning
Zaman Huri, Hasniza
Yahya, Fariz
Drug-related problems in patients with rheumatoid arthritis
title Drug-related problems in patients with rheumatoid arthritis
title_full Drug-related problems in patients with rheumatoid arthritis
title_fullStr Drug-related problems in patients with rheumatoid arthritis
title_full_unstemmed Drug-related problems in patients with rheumatoid arthritis
title_short Drug-related problems in patients with rheumatoid arthritis
title_sort drug-related problems in patients with rheumatoid arthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432894/
https://www.ncbi.nlm.nih.gov/pubmed/30962689
http://dx.doi.org/10.2147/TCRM.S194921
work_keys_str_mv AT mashuning drugrelatedproblemsinpatientswithrheumatoidarthritis
AT zamanhurihasniza drugrelatedproblemsinpatientswithrheumatoidarthritis
AT yahyafariz drugrelatedproblemsinpatientswithrheumatoidarthritis